You can view the current or previous issues of Diabetes Health online, in their entirety, anytime you want.
Click Here To View
Latest Type 2 Issues Articles
Popular Type 2 Issues Articles
Highly Recommended Type 2 Issues Articles
Send a link to this page to your friends and colleagues.
French drug maker Sanofi-aventis says that results from a Phase III trial of its experimental type 2 diabetes drug lixisenatide show that the drug successfully lowered patients' blood glucose levels and body weight, but did not increase the risk of hypoglycemia.
The Phase III study tracked 361 type 2 patients with A1C levels between 7% and 10% who were not receiving any therapy for blood glucose. The patients were divided into three groups, two that took once-daily doses of the drug at different levels of strength, and a third that received a placebo. The test lasted 12 weeks.
Sanofi says that the two groups taking the experimental drug experienced "significantly reduced" A1C levels-including levels below 7%-and "significantly improved" fasting plasma glucose and two-hour post-meal glucose.
If lixisenatide gains FDA approval to go to market, it will join a field of GLP-1 agonists that includes Amylin and Eli Lilly's Byetta (exenatide) and Novo Nordisk's Victoza (liraglutide). Financial analysts say the drug could carve out a $500 million niche in the U.S. market.
0 comments - May 23, 2011
Diabetes Health is the essential resource for people living with diabetes- both newly diagnosed and experienced as well as the professionals who care for them. We provide balanced expert news and information on living healthfully with diabetes. Each issue includes cutting-edge editorial coverage of new products, research, treatment options, and meaningful lifestyle issues.